FY2026 Earnings Forecast for BNTC Issued By Leerink Partnrs

Key Points

• Leerink Partners has lowered their FY2026 earnings per share forecast for Benitec Biopharma to ($1.14), down from a previous forecast of ($1.05), while the current consensus estimate is ($1.48).
• Benitec Biopharma's stock is currently rated as a "Buy" by most analysts, with a consensus price target of $24.80 despite a recent earnings miss of ($0.18) below estimates.
• The company's stock has seen institutional interest, with 52.19% of shares owned by hedge funds and institutional investors, indicating growing confidence in the company's potential.

Benitec Biopharma Limited (NASDAQ:BNTC - Free Report) - Research analysts at Leerink Partnrs lowered their FY2026 earnings per share (EPS) estimates for Benitec Biopharma in a note issued to investors on Monday, September 22nd. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings of ($1.14) per share for the year, down from their previous forecast of ($1.05). The consensus estimate for Benitec Biopharma's current full-year earnings is ($1.48) per share.

Several other analysts have also issued reports on the stock. JMP Securities restated a "market outperform" rating and set a $20.00 target price on shares of Benitec Biopharma in a research report on Wednesday. Oppenheimer reissued an "outperform" rating and set a $29.00 price target (down previously from $35.00) on shares of Benitec Biopharma in a report on Tuesday, September 16th. Finally, TD Cowen assumed coverage on Benitec Biopharma in a research note on Monday, July 7th. They issued a "buy" rating on the stock. One research analyst has rated the stock with a Strong Buy rating and seven have given a Buy rating to the company's stock. According to MarketBeat, Benitec Biopharma currently has a consensus rating of "Buy" and a consensus price target of $24.80.

Benitec Biopharma Stock Up 6.6%

BNTC stock opened at $14.09 on Thursday. Benitec Biopharma has a fifty-two week low of $8.49 and a fifty-two week high of $17.15. The company has a market cap of $369.86 million, a price-to-earnings ratio of -9.58 and a beta of 0.43. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.80 and a current ratio of 14.80. The business's 50-day moving average is $12.65 and its two-hundred day moving average is $13.47.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last released its quarterly earnings data on Thursday, September 25th. The biotechnology company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.18).

Hedge Funds Weigh In On Benitec Biopharma

Several institutional investors have recently bought and sold shares of BNTC. Police & Firemen s Retirement System of New Jersey purchased a new stake in Benitec Biopharma in the 2nd quarter worth $38,000. JPMorgan Chase & Co. bought a new stake in shares of Benitec Biopharma in the second quarter worth about $80,000. Bank of America Corp DE lifted its position in shares of Benitec Biopharma by 2,255.8% in the second quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company's stock worth $80,000 after buying an additional 6,587 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Benitec Biopharma during the 2nd quarter valued at approximately $93,000. Finally, New York State Common Retirement Fund bought a new stake in Benitec Biopharma in the 2nd quarter worth approximately $95,000. 52.19% of the stock is owned by hedge funds and other institutional investors.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.